The Week of

A new study published in Nature Communications found that a single 25mg dose of psilocybin produced measurable anatomical brain changes lasting at least one month after treatment.

Researchers observed denser neural connections, increased brain flexibility, and improvements in well-being and psychological insight among participants. The findings add to growing evidence that psychedelic therapies may create lasting biological changes associated with mental health improvement, an important factor for future FDA approvals and broader clinical adoption. Check it out: https://www.nature.com/articles/s41467-026-71962-3

Medical Microinstrument Inc.'s Symani robotic surgical system was used to treat the first Alzheimer’s patient in the FDA-approved REMIND study evaluating robotic microsurgery for neurodegenerative disease.

The procedure explored whether restoring lymphatic drainage pathways in the deep cervical lymph node region could improve clearance of harmful neurotoxins associated with Alzheimer’s progression. Here’s more: https://jlsfund.substack.com/p/alzheimers-research-tests-microsurgery

NRx Pharmaceuticals announced that the FDA cleared its Phase 2/3 MIND1 clinical trial evaluating NRX-101 in combination with robotic-enabled transcranial magnetic stimulation (TMS) for patients suffering from treatment-resistant depression and suicidality.

The study will test whether combining NRX-101 (an oral investigational therapy targeting suicidal bipolar depression) with AI-guided TMS can improve outcomes compared to TMS alone. The company plans to enroll roughly 400 patients across academic hospitals, military treatment facilities, and HOPE Therapeutics clinics. Check it out: https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-clearance-proceed

P.S. - Wanted to let you know that one of our portfolio companies in Fund 2, Ksana Health, recently landed a nearly $4 million investment from ARPA-H. This is a big deal.

If you’re unfamiliar, ARPA-H is essentially the U.S. government’s attempt to fast-track breakthrough medical technologies the way DARPA helped accelerate the internet, GPS, and modern defense innovation.

Not only is the infusion of capital important, but so is the recognition within government bodies that oversee these programs. https://arpa-h.gov/news-and-events/arpa-h-announces-first-research-teams-139-million-initiative-transform-behavioral

Did you know that scientists recently gave psilocybin to highly aggressive fish and found the psychedelic significantly reduced aggressive behavior toward other fish?

The study, published in Frontiers in Behavioral Neuroscience, is believed to be the first to demonstrate psilocybin-reducing aggression in an animal model, potentially offering new insight into how psychedelics may influence social behavior and mental health disorders. Here’s more: https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2026.1767175/ful